Navigation Links
Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting

ygenation, which may be exploited to increase the effectiveness of radiotherapy. The study was conducted to determine whether administration of SPI (IRL)-1620 prior to radiation enhances the efficacy of radiotherapy.

SPI (IRL)-1620 was administered in doses ranging from 1 to 9 nmol/kg via tail vein 15 minutes prior to radiation administration. Tumor diameter was measured twice a week for a total of 70 days.

Results

Control animals showed a progressive increase in tumor volume and all animals died by 53 days after tumor induction. As expected, no significant response to SPI (IRL)-1620 or to radiation therapy alone was seen. Animals treated with SPI-1620 followed by radiation experienced significantly reduced tumor volume and there was a significant increase in life span. This effect was dose proportional, with best effect seen at the higher dose.

Conclusion

Researchers concluded that SPI (IRL)-1620 significantly enhanced the efficacy of radiation treatment in mice.

Abstract #4058 -- ETB Receptor Agonist, SPI (IRL)-1620, Enhances the Efficacy of Cyclophosphamide and Cisplatin in Ovarian Tumor Bearing Mice

Ovarian cancer represents the most malignant carcinoma of the female genital tract and is often diagnosed only after the disease has reached the advanced stage. Currently, primary therapy includes surgery followed by chemotherapy. In preclinical studies, SPI (IRL)-1620 has demonstrated an enhanced efficacy of anti-neoplastic agents in breast and prostate tumor bearing rats. The present study was conducted to evaluate the effect of SPI (IRL)-1620 on the efficacy of cyclophosphamide and cisplatin in ovarian tumor bearing athymic (nu+/nu+) mice.

Results

Tumor volume of saline or SPI (IRL)-1620 alone treated mice increased at a similar rate, while cyclophosphamide and cisplatin produced reduction in tumor volume. However, SPI (IRL)-1620 administration prior to cyclophosphamide and cisplatin significantly enha
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:12/16/2009)... 17 Cell Therapeutics, Inc. (CTI) ... on February 10, 2010 the U.S. Food ... (ODAC) will review the New Drug Application ... relapsed/refractory aggressive non-Hodgkin,s lymphoma (NHL). ODAC is ... data concerning the efficacy and safety of ...
(Date:12/16/2009)... Medlytix, a national healthcare consulting firm, ... half-billion dollar milestone - the total amount of ... financial assistance to more than a half-million patients ... classifying charity care - in less than two ... hospitals enhanced their bottom lines and still were ...
(Date:12/16/2009)... Dec. 16 Ethicon, Inc., a Johnson ... and a worldwide leader in surgical care, and ... dedicated to designing, developing and commercializing devices that ... (ENT), today announced a definitive merger agreement whereby ... for approximately $785 million net of estimated cash ...
Breaking Medicine Technology:Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 2Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 3Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 4Healthcare Scoring System Allows Hospitals To Increase Charity Care 2Healthcare Scoring System Allows Hospitals To Increase Charity Care 3Healthcare Scoring System Allows Hospitals To Increase Charity Care 4Ethicon Announces Definitive Agreement to Acquire Acclarent 2Ethicon Announces Definitive Agreement to Acquire Acclarent 3Ethicon Announces Definitive Agreement to Acquire Acclarent 4ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer 3A New Hotline Report to Aid Healthcare Decision Make 6429 1ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer 3A New Hotline Report to Aid Healthcare Decision Make 6429 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer 3A New Hotline Report to Aid Healthcare Decision Make 6429 3Biologists discover bacterial defense mechanism against aggressive oxygen 10837 1Biologists discover bacterial defense mechanism against aggressive oxygen 10837 2Lehigh receives grant to reduce cost of carbon capture at coal fired power plants 10833 1Lehigh receives grant to reduce cost of carbon capture at coal fired power plants 10833 2Lehigh receives grant to reduce cost of carbon capture at coal fired power plants 10833 3
... June 25 Vical Incorporated,(Nasdaq: VICL ) ... milestones under a three-year, $6.0 million grant awarded ... a DNA vaccine manufacturing,process with the potential to ... of days., The RapidResponse(TM) system is designed ...
... Initiates a Phase I/II Study of Zalutumumab in Combination, ... Head and Neck Cancer., COPENHAGEN, June 24 ... Phase I/II study of zalutumumab,(HuMax-EGFr(TM)) in combination with radiotherapy ... study will include a maximum of 36,patients who are ...
Other Medicine Technology:Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 2Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 3Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 4Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 5Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 2Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 3
(Date:12/17/2009)... CDC,s Morbidity and Mortality Weekly Report (MMWR) released ... epidemiologists has decreased steadily since 2004, with a ... was also a substantial decrease in core epidemiology ... for bioterrorism and emergency response. For ... substance abuse, and oral health, basic epidemiology capacity ...
(Date:12/17/2009)... Good Samaritan Hospital is changing the way women manage ... of the Good Samaritan Hospital Women,s Center For Bladder ... help treat two common medical problems - lack of ... uterus or rectum (pelvic organ prolapse). Three out of ... one out of three may experience pelvic organ prolapse, ...
(Date:12/17/2009)... OAKLAND, Calif., Dec. 17 Today, SEIU ... that Alameda County In-Home Supportive Service (IHSS) providers ... contract with the County that adds multiple layers ... and benefit levels, as well as granting additional ... joining the Governor,s desire to slash homecare provider ...
(Date:12/17/2009)... WALTHAM, MA Brandeis University selected Jay and Maureen Neitz, ... the use of gene therapy to treat vision disorders, ... Award in Vision Sciences. , The award is funded ... a gift from Brandeis graduates Jay Pepose ,75 and ... supports graduate research fellowships in vision science. , The ...
(Date:12/17/2009)... hospital clients Rutherford Hospital Inc. (Rutherfordton, N.C.), a management ... management client since 1992, were recently recognized as top-ranked ... ... Brentwood, Tenn. (PRWEB) ... Rutherford Hospital Inc. (Rutherfordton, N.C.), a management client since ...
Breaking Medicine News(10 mins):Health News:CSTE National Assessment Finds Critical Public Health Disease Surveillance Capacity Lacking 2Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 2Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 3Health News:New Alameda County IHSS Contract Sends Clear Message to Elected Leaders That Homecare Program Must Remain a California Priority 2Health News:Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis 2Health News:QHR Client Hospitals in North Carolina, Michigan Lauded for Providing Community Value 2
... The Procter & Gamble,Company (NYSE: PG ... New York City,beginning at 8:30 a.m. Eastern Time. ... and the Company,s executive management team will,provide a review ... growth opportunities. , ...
... commissioned insurance sales agents in Canada are on the rise ... ... recent reports by Statistics Canada that unemployment is growing and consumer ... supplemental insurance, reports job opportunities for commissioned insurance sales agents in ...
... ... Panama City, FL (PRWEB) December 11, 2008 -- iSirona®, an ... that Peter Witonsky has been named president and chief sales officer. ... over the past 12 months. Company founder and former President Dave ...
... of Electronic Medical Record and practice billing solutions for the healthcare ... company as Chief Commercial Officer. Flormann brings 25 years of ... business and market development to Glenwood Systems. , ... ...
... OH, December 11, 2008 -- More than half a million ... and preterm births are on the rise. Late preterm ... (approximately 4 to 6 weeks before the mother,s due date), ... the large number of affected babies, many people are unaware ...
... ACEL ) today reported its financial results for the first quarter ... company recorded a net loss of approximately $2.8 million, or $0.06 ... Oct. 31., compared to a net loss of $2.7 million, or ... of fiscal 2008. Research and development expenses increased by approximately ...
Other Medicine News:Health News:P&G To Share Confidence in Long-Term Strategies and Goals at 2008 Analyst Meeting 2Health News:P&G To Share Confidence in Long-Term Strategies and Goals at 2008 Analyst Meeting 3Health News:P&G To Share Confidence in Long-Term Strategies and Goals at 2008 Analyst Meeting 4Health News:Insurance Job Opportunities Rise in Canada in Spite of Challenging Economy 2Health News:Insurance Job Opportunities Rise in Canada in Spite of Challenging Economy 3Health News:iSirona Announces New President and Chief Sales Officer 2Health News:Glenwood Systems, LLC Appoints Ron Flormann Chief Commercial Officer 2Health News:Late preterm births present serious risks to newborns 2Health News:Alfacell Reports Financial Results for First Quarter of Fiscal 2009 2Health News:Alfacell Reports Financial Results for First Quarter of Fiscal 2009 3Health News:Alfacell Reports Financial Results for First Quarter of Fiscal 2009 4Health News:Alfacell Reports Financial Results for First Quarter of Fiscal 2009 5
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: